1) At a US Trade Representative hearing on negotiating priorities for a US-UK trade agreement, the largest US drug industry group expressed strong criticisms of the UK’s pharmaceutical price negotiation system. #NHS #NHSPrivatisation #nhsnotforsale
ustr.gov/sites/default/…
ustr.gov/sites/default/…
2) It claimed that “the UK operates a health technology assessment system that significantly undervalues innovative medicines” and argued that US-UK trade agreement negotiations “provide an important opportunity” #NHS #NHSPrivatisation 
3) to ensure that government reimbursement systems provide “full market access for US products, which includes the setting of reimbursement amount on competitive market-derived pricing,or an equivalent process.” #NHS #NHSPrivatisation
